The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
The price of CytomX Therapeutics Inc (NASDAQ: CTMX) closed at $4.3 in the last session, up 5.13% from day before closing price of $4.09. In other words, the price has increased by $5.13 from its previous closing price. On the day, 4.0 million shares were traded. CTMX stock price reached its highest trading level at $4.39 during the session, while it also had its lowest trading level at $4.095.
Ratios:
We take a closer look at CTMX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 3.64 and its Current Ratio is at 3.64. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In the most recent recommendation for this company, Cantor Fitzgerald on September 22, 2025, initiated with a Overweight rating and assigned the stock a target price of $6.
On July 31, 2025, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $7.Oppenheimer initiated its Outperform rating on July 31, 2025, with a $7 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Nov 06 ’25 when McCarthy Sean A. sold 101,793 shares for $4.54 per share. The transaction valued at 461,906 led to the insider holds 987,891 shares of the business.
Sean McCarthy bought 101,793 shares of CTMX for $461,909 on Nov 06 ’25. On Jun 16 ’25, another insider, Ogden Christopher, who serves as the Chief Financial Officer of the company, sold 10,614 shares for $2.69 each. As a result, the insider received 28,540 and left with 226,271 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CTMX now has a Market Capitalization of 728572224 and an Enterprise Value of 590542208. As of this moment, CytomX’s Price-to-Earnings (P/E) ratio for their current fiscal year is 10.28. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.41 while its Price-to-Book (P/B) ratio in mrq is 6.61. Its current Enterprise Value per Revenue stands at 5.197 whereas that against EBITDA is 24.078.
Stock Price History:
The Beta on a monthly basis for CTMX is 2.43, which has changed by 3.8288074 over the last 52 weeks, in comparison to a change of 0.17287207 over the same period for the S&P500. Over the past 52 weeks, CTMX has reached a high of $4.66, while it has fallen to a 52-week low of $0.40. The 50-Day Moving Average of the stock is 5.55%, while the 200-Day Moving Average is calculated to be 63.51%.
Shares Statistics:
According to the various share statistics, CTMX traded on average about 2.93M shares per day over the past 3-months and 1841760 shares per day over the past 10 days. A total of 165.07M shares are outstanding, with a floating share count of 127.86M. Insiders hold about 24.54% of the company’s shares, while institutions hold 65.28% stake in the company. Shares short for CTMX as of 1767139200 were 23696755 with a Short Ratio of 8.09, compared to 1764288000 on 17187962. Therefore, it implies a Short% of Shares Outstanding of 23696755 and a Short% of Float of 14.49.
Earnings Estimates
The dynamic stock of CytomX Therapeutics Inc (CTMX) is currently being evaluated by a team of 7.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is -$0.1, with high estimates of -$0.08 and low estimates of -$0.11.
Analysts are recommending an EPS of between $0.02 and -$0.06 for the fiscal current year, implying an average EPS of -$0.02. EPS for the following year is -$0.36, with 7.0 analysts recommending between -$0.21 and -$0.54.
Revenue Estimates
According to 7 analysts,. The current quarter’s revenue is expected to be $7.51M. It ranges from a high estimate of $15M to a low estimate of $4M. As of. The current estimate, CytomX Therapeutics Inc’s year-ago sales were $38.09MFor the next quarter, 7 analysts are estimating revenue of $6.67M. There is a high estimate of $10M for the next quarter, whereas the lowest estimate is $4M.
A total of 7 analysts have provided revenue estimates for CTMX’s current fiscal year. The highest revenue estimate was $90.54M, while the lowest revenue estimate was $79.54M, resulting in an average revenue estimate of $83.16M. In the same quarter a year ago, actual revenue was $138.1MBased on 7 analysts’ estimates, the company’s revenue will be $30.73M in the next fiscal year. The high estimate is $80M and the low estimate is $4M.
